Head-to-head · WeighScore
Navio MD vs Tablet Health
The verdict
Navio MD takes it — 69.8/100 to 47.6/100.
Navio MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NavioMD offers compounded tirzepatide ($247/mo) plus brand-name Ozempic ($1,199/mo) and Mounjaro ($1,249/mo).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Navio MD | Tablet Health |
|---|---|---|
| WeighScore | 69.8/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #112 | #495 |
| Semaglutide | $345/mo (starting dose, brand-name) | Not disclosed |
| Tirzepatide | $189/mo (starting dose, compounded) | Not disclosed |
| Coverage | 48 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #112 · C
Strengths
- LegitScript verified with board-certified providers and US-licensed pharmacies
- Both compounded and brand-name options
- 48-state coverage
- Hours 9am–10pm EST Mon–Sun
- Transparent tiered pricing: you only pay for your current dose
Where it loses points
- Not available in Alabama and Mississippi
- Compounded option is tirzepatide only — no compounded semaglutide listed
- Also offers women's HRT (broader platform)
- Pricing is tiered by dose ('as low as'); the entry prices climb as your dose increases
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.